生存期-话题@MedSci

#生存期#

350篇内容 | 3583人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378069, encodeId=d49913e8069f6, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, objectType=article, longId=49384, objectId=e11b4938401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11b4938401, replyNumber=0, likeNumber=79, createdTime=2015-04-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11b4938401, moduleTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e11b4938401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378068, encodeId=71ed13e806825, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益, objectType=article, longId=49234, objectId=7bca4923406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca4923406, replyNumber=0, likeNumber=77, createdTime=2015-04-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca4923406, moduleTitle=Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca4923406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, objectType=article, longId=48932, objectId=982548932ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982548932ef, replyNumber=0, likeNumber=87, createdTime=2015-04-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982548932ef, moduleTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982548932ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378066, encodeId=8efc13e80660f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期, objectType=article, longId=48929, objectId=a5c648929a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c648929a3, replyNumber=0, likeNumber=79, createdTime=2015-04-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c648929a3, moduleTitle=Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5c648929a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378065, encodeId=5ff213e80655d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncology：靶向药物使霍奇金淋巴瘤患者生存期翻倍, objectType=article, longId=48443, objectId=ff284844386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff284844386, replyNumber=0, likeNumber=63, createdTime=2015-03-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff284844386, moduleTitle=Lancet Oncology：靶向药物使霍奇金淋巴瘤患者生存期翻倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff284844386)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378064, encodeId=917d13e80648c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=靶向为翼，肺癌患者生存期十年飞速提升2.4倍, objectType=article, longId=48296, objectId=18a34829658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18a34829658, replyNumber=0, likeNumber=79, createdTime=2015-03-19, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18a34829658, moduleTitle=靶向为翼，肺癌患者生存期十年飞速提升2.4倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18a34829658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA：降血压治疗2型糖尿病与延长生存期相关, objectType=article, longId=47043, objectId=78af4e043b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78af4e043b6, replyNumber=0, likeNumber=73, createdTime=2015-02-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78af4e043b6, moduleTitle=JAMA：降血压治疗2型糖尿病与延长生存期相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78af4e043b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378062, encodeId=84e313e80622a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Gut：细针抽吸活检不会导致癌灶播散，反而与生存期增加有关, objectType=article, longId=45386, objectId=503645386d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=503645386d8, replyNumber=0, likeNumber=66, createdTime=2015-01-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=503645386d8, moduleTitle=Gut：细针抽吸活检不会导致癌灶播散，反而与生存期增加有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=503645386d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378061, encodeId=dd6b13e80615b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：糖尿病可使胰腺癌患者生存期降低, objectType=article, longId=45110, objectId=f19a451107d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f19a451107d, replyNumber=0, likeNumber=93, createdTime=2015-01-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f19a451107d, moduleTitle=JCO：糖尿病可使胰腺癌患者生存期降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f19a451107d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378060, encodeId=42bc13e806064, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nature：T细胞疗法可延长白血病患者生存期？, objectType=article, longId=44934, objectId=d46844934d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d46844934d3, replyNumber=0, likeNumber=65, createdTime=2015-01-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d46844934d3, moduleTitle=Nature：T细胞疗法可延长白血病患者生存期？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d46844934d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378059, encodeId=1aeb13e80593f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, objectType=article, longId=43675, objectId=ea41436e517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea41436e517, replyNumber=0, likeNumber=81, createdTime=2014-12-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea41436e517, moduleTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea41436e517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378058, encodeId=1c0e13e8058d4, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, objectType=article, longId=42706, objectId=31cd42e06ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31cd42e06ce, replyNumber=0, likeNumber=78, createdTime=2014-11-19, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31cd42e06ce, moduleTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31cd42e06ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378057, encodeId=2ceb13e805724, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）, objectType=article, longId=42593, objectId=c717425931e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c717425931e, replyNumber=0, likeNumber=83, createdTime=2014-11-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c717425931e, moduleTitle=APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c717425931e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378056, encodeId=f99913e8056d3, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=吉非替尼靶向疗法或可提高食管癌患者的生存期, objectType=article, longId=42353, objectId=475e423530b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475e423530b, replyNumber=0, likeNumber=74, createdTime=2014-11-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475e423530b, moduleTitle=吉非替尼靶向疗法或可提高食管癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475e423530b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378055, encodeId=732a13e8055b0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA OHNS：肿瘤分级在嗅神经母细胞瘤生存期评估中的重要性, objectType=article, longId=42159, objectId=c0c74215996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0c74215996, replyNumber=0, likeNumber=55, createdTime=2014-11-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0c74215996, moduleTitle=JAMA OHNS：肿瘤分级在嗅神经母细胞瘤生存期评估中的重要性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0c74215996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378054, encodeId=a06e13e805412, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）, objectType=article, longId=40872, objectId=1489408e2f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1489408e2f5, replyNumber=0, likeNumber=77, createdTime=2014-10-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1489408e2f5, moduleTitle=ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1489408e2f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378053, encodeId=3b1c13e80537a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, objectType=article, longId=40815, objectId=525640815a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525640815a4, replyNumber=0, likeNumber=80, createdTime=2014-10-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525640815a4, moduleTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525640815a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378052, encodeId=c63f13e805298, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期, objectType=article, longId=38613, objectId=afb438613a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afb438613a7, replyNumber=0, likeNumber=93, createdTime=2014-08-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afb438613a7, moduleTitle=GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afb438613a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378051, encodeId=d11b13e805109, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, objectType=article, longId=38348, objectId=af3d38348b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3d38348b5, replyNumber=0, likeNumber=68, createdTime=2014-07-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3d38348b5, moduleTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3d38348b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378050, encodeId=d9e813e805026, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA：多重基因检测或改善靶向治疗生存期, objectType=article, longId=36274, objectId=13bf362e40c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bf362e40c, replyNumber=0, likeNumber=86, createdTime=2014-06-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bf362e40c, moduleTitle=JAMA：多重基因检测或改善靶向治疗生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bf362e40c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系

2015-04-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益

2015-04-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期

2015-04-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期

2015-04-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncology：靶向药物使霍奇金淋巴瘤患者生存期翻倍

2015-03-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

靶向为翼，肺癌患者生存期十年飞速提升2.4倍

2015-03-19

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA：降血压治疗2型糖尿病与延长生存期相关

2015-02-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Gut：细针抽吸活检不会导致癌灶播散，反而与生存期增加有关

2015-01-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCO：糖尿病可使胰腺癌患者生存期降低

2015-01-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Nature：T细胞疗法可延长白血病患者生存期？

2015-01-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期

2014-12-07

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期

2014-11-19

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

APLCC 2014：阿法替尼可延长亚洲非小细胞肺癌患者总体生存期（LUX-Lung 6研究）

2014-11-15

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

吉非替尼靶向疗法或可提高食管癌患者的生存期

2014-11-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA OHNS：肿瘤分级在嗅神经母细胞瘤生存期评估中的重要性

2014-11-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）

2014-10-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

维汀联合希罗达显著延长HER2阴性乳腺癌总生存期

2014-10-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期

2014-08-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

2014-07-30

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA：多重基因检测或改善靶向治疗生存期

2014-06-13

科室
- - 订阅+
  - 更多科室
工具
服务